By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.
Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...